Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations
- PMID: 29446198
- PMCID: PMC5903938
- DOI: 10.1002/humu.23406
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations
Abstract
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations.
Keywords: BRCA1; BRCA2; breast cancer; ethnicity; geography; mutation; ovarian cancer.
© 2018 Wiley Periodicals, Inc.
References
-
- Ah Mew N, Hamel N, Galvez M, Al-Saffar M, Foulkes WD. Haplotype analysis of a BRCA1: 185delAG mutation in a Chilean family supports its Ashkenazi origins. Clinical Genetics. 2002;62(2):151–6. - PubMed
-
- Ahn SH, Son BH, Yoon KS, Noh DY, Han W, Kim SW, Lee ES, Park HL, Hong YJ, Choi JJ, et al. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett. 2007;245(1–2):90–5. - PubMed
-
- Alemar B, Herzog J, Brinckmann Oliveira Netto C, Artigalás O, Schwartz IVD, Matzenbacher Bittar C, Ashton-Prolla P, Weitzel JN. Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations. Cancer Genet. 2016;209(9):417–422. - PubMed
-
- Anczukow O, Ware MD, Buisson M, Zetoune AB, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S. Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat. 2008;29(1):65–73. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 CA180868/CA/NCI NIH HHS/United States
- MR/P012930/1/MRC_/Medical Research Council/United Kingdom
- U10 CA037517/CA/NCI NIH HHS/United States
- 16563/CRUK_/Cancer Research UK/United Kingdom
- R01 CA102776/CA/NCI NIH HHS/United States
- U19 CA148065/CA/NCI NIH HHS/United States
- 23382/CRUK_/Cancer Research UK/United Kingdom
- R25 CA171998/CA/NCI NIH HHS/United States
- UG1 CA189867/CA/NCI NIH HHS/United States
- 203477/Z/16/Z/WT_/Wellcome Trust/United Kingdom
- R01 CA140323/CA/NCI NIH HHS/United States
- C12292/A20861/CRUK_/Cancer Research UK/United Kingdom
- R01 CA176785/CA/NCI NIH HHS/United States
- 17528/CRUK_/Cancer Research UK/United Kingdom
- RC4 CA153828/CA/NCI NIH HHS/United States
- R01 CA142996/CA/NCI NIH HHS/United States
- P50 CA125183/CA/NCI NIH HHS/United States
- UM1 CA164920/CA/NCI NIH HHS/United States
- P30 CA168524/CA/NCI NIH HHS/United States
- U01 CA161032/CA/NCI NIH HHS/United States
- C5047/A8385/CRUK_/Cancer Research UK/United Kingdom
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- 20861/CRUK_/Cancer Research UK/United Kingdom
- U10 CA027469/CA/NCI NIH HHS/United States
- C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
- UL1 TR000124/TR/NCATS NIH HHS/United States
- U01 CA116167/CA/NCI NIH HHS/United States
- C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
- P30 CA008748/CA/NCI NIH HHS/United States
- R01 CA128978/CA/NCI NIH HHS/United States
- N02 CP011019/CP/NCI NIH HHS/United States
- N02 CP065504/CP/NCI NIH HHS/United States
- 12677/CRUK_/Cancer Research UK/United Kingdom
- C1287/A 10710/CRUK_/Cancer Research UK/United Kingdom
- R01 CA083855/CA/NCI NIH HHS/United States
- U19 CA148537/CA/NCI NIH HHS/United States
- P30 CA051008/CA/NCI NIH HHS/United States
- R01 CA116167/CA/NCI NIH HHS/United States
- P50 CA116201/CA/NCI NIH HHS/United States
- U01 CA113916/CA/NCI NIH HHS/United States
- C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
- 15007/CRUK_/Cancer Research UK/United Kingdom
- P30 CA016058/CA/NCI NIH HHS/United States
- U19 CA148112/CA/NCI NIH HHS/United States
- C1281/A12014/CRUK_/Cancer Research UK/United Kingdom
- C1287/A11990/CRUK_/Cancer Research UK/United Kingdom
- UL1 TR001881/TR/NCATS NIH HHS/United States
- C8197/A16565/CRUK_/Cancer Research UK/United Kingdom
- C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
- U10 CA180822/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous